Feasibility of Early Gabapentin as an Intervention for Neurorecovery
This study is assessing the feasibility of conducting a well-designed intervention efficacy study looking at the early administration of gabapentin.
Gabapentin is a medication commonly used in spinal cord injury (SCI) to manage neuropathic pain. Emerging preclinical and clinical evidence suggests that early initiation of low to medium doses of gabapentin and continued delivery for a range of 2 weeks to 4 months has a persistent, positive effect on motor and autonomic neurologic recovery.
The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery.
This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.
Detailed study information is available at https://clinicaltrials.gov/study/NCT05302999.
For More Information
Program Contacts: Mayson Moore
Contact Number: (216) 957-3518
Contact Email: mmoore12@metrohealth.org
Contact Request
If you would like more information about becoming a research volunteer please submit the information below.